

Pacira Pharmaceuticals, Inc.  
Form 4  
August 12, 2014

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Wicki Andreas

(Last) (First) (Middle)

GOVERNORS SQUARE, SUITE  
4-212-2,, 23 LIME TREE BAY  
AVE. WEST BAY

(Street)

GRAND CAYMAN, E9 00000

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
Pacira Pharmaceuticals, Inc. [PCRX]

3. Date of Earliest Transaction  
(Month/Day/Year)  
08/08/2014

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Ownership (Instr. 4) |           |   |                   |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|--|-----------|---|-------------------|
|                                 |                                      |  |                                | (A) or (D)  | Price   |  |  |           |   |                   |
|                                 |                                      |  |                                | Code  | V   | Amount   |  |           |   |                   |
| Common Stock                    | 08/08/2014                           |  | S                              |   | 82,100  | D  | \$ 101.0001 (1)                            | 1,245,307 | I | See footnote. (2) |
| Common Stock                    | 08/11/2014                           |  | S                              |   | 30,114  | D  | \$ 101.1959 (3)                            | 1,215,193 | I | See footnote (2)  |
| Common Stock                    | 08/11/2014                           |  | S                              |   | 37,786  | D  | \$ 101.8232 (4)                            | 1,177,407 | I | See footnote. (2) |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.



## Edgar Filing: Pacira Pharmaceuticals, Inc. - Form 4

Exchange Act, or for any other purpose of Section 16 of the Exchange Act, or for any other purpose.

- (3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$100.53 to \$101.53 inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote three (3) of this Form 4.

- (4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$101.535 to \$102.29 inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote four (4) of this Form 4.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.